Combination therapy: ICI + TKI
May 13, 2025PF AE considered related to TKI
May 13, 2025AE possibly related to both ICI and TKI
G≤1 or tolerable G2
- continue both agents
- supportive care
- monitor for signs of worsening
Intolerable G2 or G≥3
- hold both ICI and TKI
- if improvement in ≤7 days (in case of axitinib) or ≤14 days (in case of cabozantinib): suspect TKI; restart ICI as indicated
- if no improvement in 14 days: suspect ICI; restart TKI as indicated
CTCAE grading
- grade 1: mild (a/paucisymptomatic)
- grade 2: moderate (minimal symptoms)
- grade 3: severe (hospitalisation often required)
- grade 4: life threatening